[144] Emergent Biosolutions, Inc. SEC Filing

Rhea-AI Filing Summary

Emergent Biosolutions (EBS) reported a Form 144 notice to sell restricted common stock. The filing shows an intended sale of 7,086 shares with an aggregate market value of $62,852.82, representing part of a total 53,351,099 shares outstanding. The proposed approximate sale date is 08/15/2025 on the NYSE through Morgan Stanley Smith Barney LLC. The shares to be sold were acquired as restricted stock: 6,101 shares on 05/08/2025 and 985 shares on 05/25/2025, with payment recorded on the acquisition dates. The filer reports no securities sold by the same person during the past three months and makes the required representation about material nonpublic information.

Positive

• Sale size is small relative to outstanding shares (7,086 vs 53,351,099), implying limited market impact
• Transaction uses a major broker (Morgan Stanley Smith Barney LLC), indicating standard institutional execution
• No reported sales in prior three months by the same person, suggesting this may be a one-off or routine disposition

Negative

• None.

Insights

Securities Analyst

TL;DR: Insiders intend a modest, scheduled sale of newly acquired restricted shares; impact appears limited.

The Form 144 shows a proposed sale of 7,086 restricted shares valued at $62,852.82, traded via a major brokerage on the NYSE. The shares were acquired in May 2025 as restricted awards, indicating these are recent insider-held grants being registered for sale. Because the quantity is small relative to the 53.35 million shares outstanding, the dilution or market impact is likely minimal. No prior sales in the past three months are reported by the same person, which suggests this is a routine disposition rather than continued selling pressure. The filing contains only transaction details and the required insider certification; it does not disclose the filer’s identity or intent beyond the sale notice.

Corporate Governance Specialist

TL;DR: Filing documents compliance with Rule 144 for disposal of restricted stock; procedural, not material governance change.

The notice documents compliance steps for an insider or affiliated person to sell restricted shares under Rule 144, including acquisition dates and nature of acquisition as restricted stock. The absence of sales in the prior three months and explicit broker details support that this is a standard, rule-compliant transaction. The filing contains the standard representation regarding material nonpublic information. There is no disclosure of any executive departure, change in control, or governance action in this Form 144.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	7086	62852.82	53351099	08/15/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/25/2025	Restricted Stock	Issuer			985	05/25/2025	Not Applicable
Common	05/08/2025	Restricted Stock	Issuer			6101	05/08/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for Emergent Biosolutions (EBS) disclose?

The Form 144 discloses a proposed sale of 7,086 common shares valued at $62,852.82, to be sold approximately on 08/15/2025 on the NYSE through Morgan Stanley Smith Barney LLC.

How were the shares being sold acquired according to the filing?

The filing states the shares were acquired as restricted stock: 6,101 shares on 05/08/2025 and 985 shares on 05/25/2025, with payment recorded on those dates.

Does the filer report other sales in the past three months?

The filing reports "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

What exchange will the shares be sold on?

The proposed sale is listed for the NYSE.

What representation does the filer make about material information?

By signing, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.